Pharvaris (PHVS)

Its lead drug candidate is deucrictibant, an oral small-molecule bradykinin B2 receptor antagonist. Pharvaris is developing the therapy for both on-demand treatment of HAE attacks and prevention of future attacks. This oral approach is intended to offer an alternative to injectable or infused therapies used in the HAE market, with the goal of improving convenience for patients while maintaining effective control of symptoms.

The company has reported positive Phase 2 data in both prophylactic and on-demand settings and is advancing deucrictibant through late-stage development. Pharvaris is enrolling a pivotal Phase 3 trial for the treatment of HAE attacks and plans to begin a pivotal Phase 3 study evaluating deucrictibant for prevention. It is also conducting open-label extension studies, including RAPIDe-2 for on-demand use and CHAPTER-4 for prophylaxis, to gather longer-term safety and efficacy information.

Pharvaris’ investment profile is shaped by clinical trial execution, regulatory review, and the competitive landscape in rare disease therapeutics. Its value proposition rests on whether deucrictibant can demonstrate durable clinical benefit, acceptable safety, and meaningful convenience for HAE patients and physicians.